| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphedema | 26 | 2017 | 239 | 6.010 |
Why?
|
| Melanoma | 74 | 2020 | 5317 | 4.350 |
Why?
|
| Skin Neoplasms | 46 | 2020 | 4654 | 2.790 |
Why?
|
| Sarcoma | 35 | 2019 | 1725 | 2.340 |
Why?
|
| Lymph Node Excision | 18 | 2016 | 1959 | 1.860 |
Why?
|
| Sentinel Lymph Node Biopsy | 18 | 2017 | 1415 | 1.750 |
Why?
|
| Colonic Neoplasms | 10 | 2018 | 1390 | 1.400 |
Why?
|
| Quality of Life | 16 | 2015 | 4532 | 1.370 |
Why?
|
| Neoplasm Staging | 64 | 2020 | 13658 | 1.350 |
Why?
|
| Retroperitoneal Neoplasms | 13 | 2019 | 262 | 1.290 |
Why?
|
| Lymphatic Metastasis | 28 | 2018 | 4844 | 1.030 |
Why?
|
| Neoplasm Recurrence, Local | 32 | 2020 | 10035 | 0.980 |
Why?
|
| Breast Neoplasms | 28 | 2016 | 15694 | 0.970 |
Why?
|
| Guideline Adherence | 4 | 2017 | 636 | 0.920 |
Why?
|
| Preoperative Care | 10 | 2018 | 1529 | 0.900 |
Why?
|
| Soft Tissue Neoplasms | 10 | 2019 | 882 | 0.840 |
Why?
|
| Extremities | 7 | 2019 | 303 | 0.840 |
Why?
|
| Surveys and Questionnaires | 13 | 2015 | 5687 | 0.830 |
Why?
|
| Middle Aged | 121 | 2020 | 86204 | 0.820 |
Why?
|
| Lymphatic Vessels | 3 | 2011 | 143 | 0.820 |
Why?
|
| Aged | 115 | 2020 | 70117 | 0.780 |
Why?
|
| Humans | 208 | 2020 | 261506 | 0.770 |
Why?
|
| Female | 150 | 2020 | 141928 | 0.750 |
Why?
|
| Lymph Nodes | 10 | 2017 | 2967 | 0.740 |
Why?
|
| SEER Program | 15 | 2015 | 1000 | 0.730 |
Why?
|
| Survival Analysis | 25 | 2019 | 9180 | 0.720 |
Why?
|
| Aged, 80 and over | 69 | 2020 | 29902 | 0.710 |
Why?
|
| Prognosis | 50 | 2020 | 21713 | 0.710 |
Why?
|
| Liposarcoma | 6 | 2019 | 214 | 0.700 |
Why?
|
| Survivors | 5 | 2015 | 1031 | 0.690 |
Why?
|
| Male | 131 | 2020 | 123000 | 0.660 |
Why?
|
| Adult | 91 | 2020 | 77950 | 0.640 |
Why?
|
| Self Care | 4 | 2014 | 224 | 0.620 |
Why?
|
| Quality of Health Care | 5 | 2018 | 621 | 0.620 |
Why?
|
| Incidence | 21 | 2020 | 5673 | 0.620 |
Why?
|
| Neoplasms | 18 | 2017 | 15193 | 0.610 |
Why?
|
| Carcinoma, Lobular | 2 | 2015 | 611 | 0.610 |
Why?
|
| Adenocarcinoma | 13 | 2018 | 7789 | 0.600 |
Why?
|
| Follow-Up Studies | 40 | 2019 | 14889 | 0.600 |
Why?
|
| Inguinal Canal | 3 | 2014 | 60 | 0.600 |
Why?
|
| Mastectomy | 5 | 2015 | 1534 | 0.600 |
Why?
|
| Survival Rate | 44 | 2018 | 12221 | 0.580 |
Why?
|
| Postoperative Complications | 9 | 2019 | 5542 | 0.570 |
Why?
|
| Practice Guidelines as Topic | 6 | 2017 | 2403 | 0.570 |
Why?
|
| Cohort Studies | 25 | 2020 | 9244 | 0.530 |
Why?
|
| Intestinal Obstruction | 3 | 2017 | 202 | 0.530 |
Why?
|
| Plant Preparations | 1 | 2014 | 36 | 0.500 |
Why?
|
| Adaptation, Psychological | 3 | 2015 | 764 | 0.500 |
Why?
|
| Odds Ratio | 11 | 2016 | 2316 | 0.490 |
Why?
|
| Prospective Studies | 24 | 2017 | 12873 | 0.480 |
Why?
|
| Torso | 4 | 2019 | 73 | 0.480 |
Why?
|
| Proportional Hazards Models | 15 | 2018 | 4988 | 0.470 |
Why?
|
| Phytotherapy | 1 | 2014 | 110 | 0.470 |
Why?
|
| Gastrointestinal Stromal Tumors | 5 | 2018 | 297 | 0.470 |
Why?
|
| Gastrointestinal Neoplasms | 7 | 2018 | 600 | 0.460 |
Why?
|
| Treatment Outcome | 41 | 2019 | 32848 | 0.460 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2012 | 1303 | 0.440 |
Why?
|
| Health Resources | 2 | 2013 | 168 | 0.430 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2012 | 43 | 0.420 |
Why?
|
| United States | 30 | 2020 | 15433 | 0.410 |
Why?
|
| Surgical Wound Infection | 3 | 2012 | 450 | 0.410 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 552 | 0.410 |
Why?
|
| Retrospective Studies | 46 | 2019 | 37905 | 0.410 |
Why?
|
| Neoplasms, Radiation-Induced | 4 | 2016 | 388 | 0.410 |
Why?
|
| Young Adult | 31 | 2020 | 21445 | 0.410 |
Why?
|
| Geriatric Assessment | 1 | 2013 | 275 | 0.410 |
Why?
|
| Disease-Free Survival | 22 | 2019 | 10001 | 0.400 |
Why?
|
| Abdomen | 1 | 2013 | 332 | 0.400 |
Why?
|
| Population Surveillance | 3 | 2012 | 627 | 0.400 |
Why?
|
| Rectal Neoplasms | 6 | 2018 | 1202 | 0.400 |
Why?
|
| Models, Statistical | 4 | 2016 | 1171 | 0.390 |
Why?
|
| Antigens, Neoplasm | 10 | 1999 | 1506 | 0.380 |
Why?
|
| Healthcare Disparities | 5 | 2018 | 598 | 0.380 |
Why?
|
| Delivery of Health Care | 3 | 2013 | 860 | 0.380 |
Why?
|
| Axilla | 6 | 2016 | 902 | 0.380 |
Why?
|
| Medicine | 1 | 2012 | 137 | 0.370 |
Why?
|
| Leiomyosarcoma | 3 | 2017 | 223 | 0.370 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2019 | 992 | 0.360 |
Why?
|
| Appendiceal Neoplasms | 1 | 2012 | 234 | 0.350 |
Why?
|
| Anus Diseases | 1 | 2009 | 29 | 0.350 |
Why?
|
| Rectal Diseases | 1 | 2009 | 55 | 0.350 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2010 | 129 | 0.350 |
Why?
|
| Neoadjuvant Therapy | 13 | 2018 | 4975 | 0.350 |
Why?
|
| Neuroendocrine Tumors | 2 | 2012 | 634 | 0.340 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2009 | 41 | 0.340 |
Why?
|
| Chemotherapy, Adjuvant | 18 | 2018 | 3890 | 0.340 |
Why?
|
| Databases, Factual | 9 | 2019 | 2218 | 0.340 |
Why?
|
| Adolescent | 32 | 2020 | 31252 | 0.340 |
Why?
|
| Positron-Emission Tomography | 4 | 2014 | 2173 | 0.340 |
Why?
|
| Health Services Accessibility | 2 | 2016 | 761 | 0.330 |
Why?
|
| Sickness Impact Profile | 2 | 2012 | 139 | 0.330 |
Why?
|
| C-Reactive Protein | 3 | 2017 | 527 | 0.320 |
Why?
|
| Seroma | 1 | 2008 | 79 | 0.320 |
Why?
|
| Cost-Benefit Analysis | 7 | 2015 | 945 | 0.320 |
Why?
|
| Neoplasm Proteins | 10 | 1999 | 3230 | 0.320 |
Why?
|
| Disabled Persons | 2 | 2013 | 121 | 0.320 |
Why?
|
| Combined Modality Therapy | 19 | 2018 | 8865 | 0.320 |
Why?
|
| Health Surveys | 2 | 2016 | 402 | 0.320 |
Why?
|
| Hemangiosarcoma | 2 | 2012 | 234 | 0.310 |
Why?
|
| Self Report | 2 | 2013 | 756 | 0.310 |
Why?
|
| Lower Extremity | 6 | 2014 | 299 | 0.300 |
Why?
|
| Intestinal Perforation | 1 | 2007 | 102 | 0.290 |
Why?
|
| Antineoplastic Agents | 14 | 2015 | 14289 | 0.290 |
Why?
|
| Neoplasm Metastasis | 10 | 2018 | 5112 | 0.280 |
Why?
|
| Histiocytoma, Malignant Fibrous | 3 | 2016 | 51 | 0.280 |
Why?
|
| Intraoperative Period | 1 | 2006 | 246 | 0.280 |
Why?
|
| Quality Control | 3 | 2012 | 457 | 0.280 |
Why?
|
| Risk Assessment | 10 | 2020 | 6869 | 0.280 |
Why?
|
| Multivariate Analysis | 12 | 2020 | 4298 | 0.280 |
Why?
|
| Reproducibility of Results | 9 | 2015 | 6009 | 0.270 |
Why?
|
| Health Status Disparities | 4 | 2016 | 291 | 0.270 |
Why?
|
| Interferons | 1 | 2007 | 291 | 0.270 |
Why?
|
| Cytodiagnosis | 1 | 2006 | 220 | 0.270 |
Why?
|
| Bacterial Infections | 1 | 2009 | 479 | 0.260 |
Why?
|
| Sensitivity and Specificity | 6 | 2015 | 4971 | 0.260 |
Why?
|
| Interleukin-12 Subunit p40 | 2 | 2015 | 29 | 0.260 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 2012 | 1016 | 0.260 |
Why?
|
| Risk Factors | 18 | 2020 | 17523 | 0.260 |
Why?
|
| Colectomy | 2 | 2018 | 288 | 0.250 |
Why?
|
| Logistic Models | 10 | 2018 | 3441 | 0.250 |
Why?
|
| Interleukin-2 | 4 | 2012 | 842 | 0.250 |
Why?
|
| Confidence Intervals | 7 | 2018 | 756 | 0.250 |
Why?
|
| Psychometrics | 5 | 2013 | 937 | 0.240 |
Why?
|
| Palliative Care | 3 | 2012 | 2037 | 0.240 |
Why?
|
| Bayes Theorem | 4 | 2016 | 1021 | 0.240 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2006 | 192 | 0.240 |
Why?
|
| Immunologic Factors | 1 | 2008 | 649 | 0.240 |
Why?
|
| Membrane Glycoproteins | 5 | 2006 | 1073 | 0.240 |
Why?
|
| Interferon-alpha | 1 | 2008 | 889 | 0.240 |
Why?
|
| Tumor Burden | 5 | 2019 | 1987 | 0.230 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 1162 | 0.230 |
Why?
|
| Salvage Therapy | 5 | 2018 | 2054 | 0.230 |
Why?
|
| Body Mass Index | 3 | 2017 | 2203 | 0.230 |
Why?
|
| Age Factors | 9 | 2016 | 5377 | 0.230 |
Why?
|
| Retroperitoneal Space | 2 | 2017 | 145 | 0.220 |
Why?
|
| Models, Theoretical | 1 | 2007 | 785 | 0.220 |
Why?
|
| Colorectal Neoplasms | 4 | 2015 | 3578 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2018 | 15862 | 0.220 |
Why?
|
| Physical Therapy Modalities | 2 | 2013 | 95 | 0.220 |
Why?
|
| Intermittent Pneumatic Compression Devices | 2 | 2012 | 11 | 0.210 |
Why?
|
| Evidence-Based Medicine | 4 | 2017 | 1085 | 0.210 |
Why?
|
| Stomach Neoplasms | 5 | 2018 | 2278 | 0.210 |
Why?
|
| Educational Status | 3 | 2014 | 397 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 10 | 2014 | 2231 | 0.210 |
Why?
|
| Registries | 5 | 2018 | 2170 | 0.210 |
Why?
|
| Societies, Medical | 1 | 2008 | 1335 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2014 | 7551 | 0.200 |
Why?
|
| Quality Indicators, Health Care | 2 | 2015 | 348 | 0.200 |
Why?
|
| Models, Nursing | 1 | 2001 | 9 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2015 | 7702 | 0.200 |
Why?
|
| Total Quality Management | 1 | 2001 | 34 | 0.190 |
Why?
|
| Length of Stay | 5 | 2018 | 1900 | 0.190 |
Why?
|
| Anthracyclines | 2 | 2015 | 331 | 0.190 |
Why?
|
| Ifosfamide | 1 | 2001 | 344 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 4 | 2012 | 4367 | 0.190 |
Why?
|
| Socioeconomic Factors | 7 | 2015 | 1225 | 0.190 |
Why?
|
| Age of Onset | 2 | 2013 | 827 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 6 | 2018 | 3981 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2020 | 5539 | 0.180 |
Why?
|
| Longitudinal Studies | 3 | 2015 | 1945 | 0.180 |
Why?
|
| Clinical Protocols | 3 | 2018 | 467 | 0.180 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2015 | 226 | 0.180 |
Why?
|
| Genetic Variation | 4 | 2006 | 2086 | 0.180 |
Why?
|
| Social Class | 3 | 2016 | 310 | 0.180 |
Why?
|
| Risk | 5 | 2016 | 1972 | 0.170 |
Why?
|
| Orthopedic Procedures | 1 | 2001 | 146 | 0.170 |
Why?
|
| Medical Oncology | 1 | 2008 | 1423 | 0.170 |
Why?
|
| Hospice Care | 2 | 2011 | 156 | 0.170 |
Why?
|
| Biomarkers, Tumor | 6 | 2020 | 10331 | 0.170 |
Why?
|
| Pancreatectomy | 2 | 2019 | 652 | 0.170 |
Why?
|
| Nomograms | 2 | 2013 | 313 | 0.170 |
Why?
|
| Wound Healing | 3 | 2017 | 815 | 0.170 |
Why?
|
| Pancreatic Fistula | 1 | 2019 | 99 | 0.170 |
Why?
|
| Time Factors | 13 | 2015 | 12926 | 0.170 |
Why?
|
| Health Status Indicators | 2 | 2011 | 224 | 0.170 |
Why?
|
| Piperazines | 4 | 2011 | 2101 | 0.170 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 1999 | 235 | 0.160 |
Why?
|
| MART-1 Antigen | 8 | 1999 | 105 | 0.160 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 53 | 0.160 |
Why?
|
| Quantitative Trait Loci | 1 | 2020 | 374 | 0.160 |
Why?
|
| Immunity, Cellular | 2 | 2019 | 419 | 0.160 |
Why?
|
| Interleukin-9 | 1 | 2018 | 37 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2011 | 5319 | 0.160 |
Why?
|
| HLA-A2 Antigen | 2 | 1999 | 159 | 0.160 |
Why?
|
| Upper Extremity | 4 | 2014 | 87 | 0.160 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 77 | 0.160 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2001 | 588 | 0.160 |
Why?
|
| Monophenol Monooxygenase | 1 | 1998 | 59 | 0.160 |
Why?
|
| Exercise Therapy | 2 | 2011 | 288 | 0.160 |
Why?
|
| Chemokines | 1 | 2019 | 314 | 0.150 |
Why?
|
| Health Care Costs | 3 | 2014 | 674 | 0.150 |
Why?
|
| Skin Care | 2 | 2017 | 18 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2014 | 1756 | 0.150 |
Why?
|
| Cancer Care Facilities | 3 | 2018 | 884 | 0.140 |
Why?
|
| Oximes | 1 | 2018 | 175 | 0.140 |
Why?
|
| Occupational Injuries | 1 | 2016 | 18 | 0.140 |
Why?
|
| Ergonomics | 1 | 2016 | 30 | 0.140 |
Why?
|
| Perioperative Care | 1 | 2001 | 451 | 0.140 |
Why?
|
| Computer Simulation | 2 | 2015 | 1529 | 0.140 |
Why?
|
| Neurofibrosarcoma | 1 | 2016 | 33 | 0.140 |
Why?
|
| Neoplasm Grading | 6 | 2018 | 1742 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2020 | 4549 | 0.140 |
Why?
|
| Pyrimidinones | 1 | 2018 | 314 | 0.140 |
Why?
|
| Patient Satisfaction | 2 | 2012 | 915 | 0.130 |
Why?
|
| Rectum | 1 | 2018 | 467 | 0.130 |
Why?
|
| Dopamine | 1 | 1997 | 312 | 0.130 |
Why?
|
| Occupational Diseases | 1 | 2016 | 130 | 0.130 |
Why?
|
| Insurance Coverage | 1 | 2018 | 256 | 0.130 |
Why?
|
| Pyridones | 1 | 2018 | 348 | 0.130 |
Why?
|
| Pyrimidines | 4 | 2011 | 3518 | 0.130 |
Why?
|
| Vascular Neoplasms | 1 | 2016 | 114 | 0.130 |
Why?
|
| Brachytherapy | 3 | 2012 | 977 | 0.130 |
Why?
|
| Child | 14 | 2016 | 29154 | 0.130 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2020 | 502 | 0.130 |
Why?
|
| Health Status | 2 | 2011 | 590 | 0.130 |
Why?
|
| Medicare | 3 | 2015 | 860 | 0.130 |
Why?
|
| Rehabilitation Nursing | 1 | 2014 | 9 | 0.130 |
Why?
|
| Arm | 1 | 2015 | 147 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2018 | 6207 | 0.130 |
Why?
|
| Neurofibromatosis 1 | 1 | 2016 | 144 | 0.130 |
Why?
|
| Liver Neoplasms | 2 | 2015 | 4557 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 1586 | 0.120 |
Why?
|
| Texas | 5 | 2018 | 6311 | 0.120 |
Why?
|
| Sex Factors | 4 | 2015 | 2139 | 0.120 |
Why?
|
| Carcinoma, Signet Ring Cell | 2 | 2014 | 170 | 0.120 |
Why?
|
| Lung Neoplasms | 7 | 2013 | 11538 | 0.120 |
Why?
|
| Frailty | 1 | 2016 | 113 | 0.120 |
Why?
|
| Case-Control Studies | 9 | 2020 | 6100 | 0.120 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 657 | 0.120 |
Why?
|
| Surgical Oncology | 1 | 2016 | 190 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2010 | 5437 | 0.120 |
Why?
|
| Ipilimumab | 1 | 2018 | 710 | 0.120 |
Why?
|
| Urogenital Neoplasms | 1 | 2014 | 108 | 0.120 |
Why?
|
| Vitamin D | 1 | 2016 | 261 | 0.120 |
Why?
|
| Skilled Nursing Facilities | 1 | 2013 | 13 | 0.120 |
Why?
|
| Platinum Compounds | 1 | 2014 | 131 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2006 | 2027 | 0.120 |
Why?
|
| Neck Dissection | 1 | 2014 | 290 | 0.110 |
Why?
|
| Heart Diseases | 2 | 2010 | 732 | 0.110 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2014 | 106 | 0.110 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 399 | 0.110 |
Why?
|
| Reoperation | 1 | 2018 | 1382 | 0.110 |
Why?
|
| Imagination | 1 | 2013 | 21 | 0.110 |
Why?
|
| Video-Assisted Surgery | 1 | 2013 | 28 | 0.110 |
Why?
|
| Abdominal Neoplasms | 1 | 2015 | 231 | 0.110 |
Why?
|
| Pilot Projects | 3 | 2016 | 2803 | 0.110 |
Why?
|
| Organ Sparing Treatments | 2 | 2014 | 277 | 0.110 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2015 | 363 | 0.110 |
Why?
|
| Income | 1 | 2014 | 222 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 482 | 0.110 |
Why?
|
| Self Efficacy | 1 | 2015 | 298 | 0.110 |
Why?
|
| Sexuality | 1 | 2012 | 38 | 0.110 |
Why?
|
| Medical Errors | 1 | 2015 | 219 | 0.110 |
Why?
|
| Pain | 2 | 2012 | 1658 | 0.110 |
Why?
|
| Compression Bandages | 1 | 2012 | 10 | 0.110 |
Why?
|
| Ultrasonography, Mammary | 1 | 2015 | 380 | 0.110 |
Why?
|
| Cost of Illness | 2 | 2013 | 498 | 0.110 |
Why?
|
| Disease Progression | 6 | 2018 | 6682 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 3 | 2014 | 3976 | 0.110 |
Why?
|
| Travel | 1 | 2014 | 190 | 0.110 |
Why?
|
| Polymorphism, Genetic | 3 | 2006 | 1450 | 0.110 |
Why?
|
| Lymphocyte Subsets | 1 | 2012 | 137 | 0.110 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 2011 | 169 | 0.110 |
Why?
|
| Penis | 1 | 2013 | 123 | 0.110 |
Why?
|
| Morbidity | 1 | 2013 | 397 | 0.110 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2014 | 436 | 0.110 |
Why?
|
| Lymphatic System | 1 | 2012 | 64 | 0.100 |
Why?
|
| Imidazoles | 1 | 2018 | 999 | 0.100 |
Why?
|
| Diet, Reducing | 1 | 2012 | 87 | 0.100 |
Why?
|
| Insurance, Health | 1 | 2014 | 250 | 0.100 |
Why?
|
| Deoxycytidine | 2 | 2015 | 1353 | 0.100 |
Why?
|
| Decision Support Techniques | 2 | 2007 | 622 | 0.100 |
Why?
|
| Laparoscopy | 2 | 2013 | 1225 | 0.100 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 2265 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2015 | 1546 | 0.100 |
Why?
|
| Patient Care | 1 | 2012 | 149 | 0.100 |
Why?
|
| Fluorescence | 1 | 2011 | 195 | 0.100 |
Why?
|
| Penile Neoplasms | 1 | 2013 | 161 | 0.100 |
Why?
|
| Radiography | 3 | 2011 | 1904 | 0.100 |
Why?
|
| Insurance Claim Reporting | 1 | 2010 | 17 | 0.100 |
Why?
|
| Dermatology | 1 | 2011 | 70 | 0.100 |
Why?
|
| gp100 Melanoma Antigen | 4 | 1998 | 88 | 0.100 |
Why?
|
| Amifostine | 1 | 2011 | 97 | 0.100 |
Why?
|
| Peritoneal Neoplasms | 2 | 2008 | 821 | 0.100 |
Why?
|
| Child, Preschool | 7 | 2016 | 16273 | 0.090 |
Why?
|
| Radiation-Protective Agents | 1 | 2011 | 128 | 0.090 |
Why?
|
| Disease Management | 2 | 2013 | 1052 | 0.090 |
Why?
|
| Medical Audit | 1 | 2011 | 188 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 4757 | 0.090 |
Why?
|
| California | 1 | 2010 | 208 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2018 | 1763 | 0.090 |
Why?
|
| Pain Measurement | 2 | 2012 | 953 | 0.090 |
Why?
|
| Statistics as Topic | 2 | 2009 | 445 | 0.090 |
Why?
|
| Marital Status | 1 | 2010 | 98 | 0.090 |
Why?
|
| Taxoids | 1 | 2014 | 967 | 0.090 |
Why?
|
| Age Distribution | 1 | 2011 | 698 | 0.090 |
Why?
|
| Carcinoid Tumor | 1 | 2012 | 280 | 0.090 |
Why?
|
| Anal Canal | 1 | 2011 | 238 | 0.090 |
Why?
|
| Health Policy | 1 | 2013 | 291 | 0.090 |
Why?
|
| Cytokines | 1 | 2019 | 2809 | 0.090 |
Why?
|
| Xerostomia | 1 | 2011 | 190 | 0.090 |
Why?
|
| Carcinoma, Large Cell | 1 | 2010 | 94 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2014 | 585 | 0.090 |
Why?
|
| Movement | 1 | 2013 | 556 | 0.090 |
Why?
|
| Consensus | 1 | 2013 | 978 | 0.090 |
Why?
|
| Analysis of Variance | 5 | 2008 | 2307 | 0.090 |
Why?
|
| Surgeons | 1 | 2016 | 519 | 0.090 |
Why?
|
| Social Support | 2 | 2012 | 560 | 0.090 |
Why?
|
| Mammography | 1 | 2015 | 1010 | 0.090 |
Why?
|
| Karnofsky Performance Status | 1 | 2009 | 175 | 0.090 |
Why?
|
| Demography | 1 | 2010 | 435 | 0.090 |
Why?
|
| Inflammation | 1 | 2019 | 2522 | 0.090 |
Why?
|
| Infant | 5 | 2016 | 13310 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.080 |
Why?
|
| Robotics | 1 | 2013 | 359 | 0.080 |
Why?
|
| Weight Loss | 1 | 2013 | 627 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2001 | 2576 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 2 | 2018 | 1350 | 0.080 |
Why?
|
| Enterocolitis, Neutropenic | 1 | 2008 | 19 | 0.080 |
Why?
|
| Electric Impedance | 1 | 2009 | 100 | 0.080 |
Why?
|
| Imatinib Mesylate | 5 | 2015 | 1665 | 0.080 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2008 | 26 | 0.080 |
Why?
|
| Lymphatic Irradiation | 1 | 2008 | 133 | 0.080 |
Why?
|
| Groin | 1 | 2008 | 74 | 0.080 |
Why?
|
| Kidney | 1 | 1997 | 2146 | 0.080 |
Why?
|
| Tissue Adhesives | 1 | 2008 | 51 | 0.080 |
Why?
|
| Suction | 1 | 2008 | 104 | 0.080 |
Why?
|
| Poxviridae | 2 | 1998 | 7 | 0.080 |
Why?
|
| Patient Participation | 1 | 2012 | 446 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2330 | 0.080 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 550 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2012 | 554 | 0.080 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2008 | 35 | 0.080 |
Why?
|
| Radionuclide Imaging | 1 | 2009 | 660 | 0.080 |
Why?
|
| Prevalence | 1 | 2015 | 3260 | 0.080 |
Why?
|
| Benchmarking | 1 | 2009 | 273 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2003 | 2326 | 0.070 |
Why?
|
| Mitoxantrone | 1 | 2007 | 216 | 0.070 |
Why?
|
| Cells, Cultured | 6 | 2012 | 5637 | 0.070 |
Why?
|
| Cross Infection | 1 | 2012 | 544 | 0.070 |
Why?
|
| Immunohistochemistry | 5 | 2016 | 7548 | 0.070 |
Why?
|
| Radiotherapy | 2 | 2015 | 1824 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 1258 | 0.070 |
Why?
|
| Anus Neoplasms | 1 | 2011 | 411 | 0.070 |
Why?
|
| Markov Chains | 1 | 2007 | 175 | 0.070 |
Why?
|
| Health Services Research | 1 | 2008 | 233 | 0.070 |
Why?
|
| Physical Examination | 1 | 2008 | 299 | 0.070 |
Why?
|
| Hyperthermia, Induced | 2 | 2011 | 510 | 0.070 |
Why?
|
| Tumor Necrosis Factors | 1 | 2006 | 34 | 0.070 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2006 | 66 | 0.070 |
Why?
|
| Genital Neoplasms, Female | 1 | 2012 | 735 | 0.070 |
Why?
|
| Receptors, Calcitriol | 1 | 2006 | 134 | 0.070 |
Why?
|
| Chromatids | 1 | 2005 | 78 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 1209 | 0.070 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1999 | 675 | 0.070 |
Why?
|
| Abdominal Pain | 1 | 2008 | 369 | 0.070 |
Why?
|
| Pelvis | 1 | 2007 | 362 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 446 | 0.070 |
Why?
|
| Epitopes | 2 | 1999 | 685 | 0.070 |
Why?
|
| Neoplasm Seeding | 1 | 2005 | 66 | 0.060 |
Why?
|
| Genotype | 4 | 2020 | 4109 | 0.060 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2006 | 181 | 0.060 |
Why?
|
| Biometry | 1 | 2006 | 241 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 4892 | 0.060 |
Why?
|
| Kidney Neoplasms | 2 | 2002 | 3022 | 0.060 |
Why?
|
| Health Personnel | 1 | 2010 | 625 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 543 | 0.060 |
Why?
|
| Exercise | 1 | 2012 | 1183 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2006 | 324 | 0.060 |
Why?
|
| Thoracic Neoplasms | 1 | 2007 | 337 | 0.060 |
Why?
|
| Interferon-gamma | 3 | 1998 | 1144 | 0.060 |
Why?
|
| Immunotherapy | 1 | 1998 | 3341 | 0.060 |
Why?
|
| Emotions | 1 | 2008 | 562 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2010 | 1863 | 0.060 |
Why?
|
| Probability | 1 | 2005 | 866 | 0.060 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2018 | 565 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 4 | 1999 | 5395 | 0.060 |
Why?
|
| Bevacizumab | 1 | 2007 | 938 | 0.060 |
Why?
|
| Neutropenia | 1 | 2008 | 968 | 0.060 |
Why?
|
| Biopsy, Needle | 2 | 2005 | 1363 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2014 | 4078 | 0.060 |
Why?
|
| Cisplatin | 2 | 2010 | 2432 | 0.060 |
Why?
|
| Ultraviolet Rays | 1 | 2005 | 575 | 0.060 |
Why?
|
| Prostatectomy | 1 | 2008 | 962 | 0.060 |
Why?
|
| Heart | 1 | 2010 | 1223 | 0.060 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2008 | 489 | 0.060 |
Why?
|
| Minority Groups | 1 | 2005 | 322 | 0.060 |
Why?
|
| Propensity Score | 2 | 2018 | 750 | 0.060 |
Why?
|
| Leg | 1 | 2004 | 226 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2016 | 2292 | 0.050 |
Why?
|
| Obesity | 2 | 2017 | 2884 | 0.050 |
Why?
|
| Prostatic Neoplasms | 3 | 2013 | 5767 | 0.050 |
Why?
|
| Melanoma-Specific Antigens | 2 | 1999 | 82 | 0.050 |
Why?
|
| Patient Readmission | 2 | 2018 | 548 | 0.050 |
Why?
|
| Benzamides | 4 | 2011 | 1832 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2010 | 1411 | 0.050 |
Why?
|
| Truth Disclosure | 1 | 2004 | 180 | 0.050 |
Why?
|
| Medical Records | 3 | 2008 | 415 | 0.050 |
Why?
|
| Pancreatic Ducts | 1 | 2003 | 122 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2009 | 1000 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2003 | 479 | 0.050 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2001 | 73 | 0.050 |
Why?
|
| Magnesium | 1 | 2002 | 160 | 0.050 |
Why?
|
| Orthopedic Nursing | 1 | 2001 | 1 | 0.050 |
Why?
|
| Nursing, Supervisory | 1 | 2001 | 2 | 0.050 |
Why?
|
| Operating Room Nursing | 1 | 2001 | 3 | 0.050 |
Why?
|
| Hospitals, Religious | 1 | 2001 | 7 | 0.050 |
Why?
|
| Nursing Evaluation Research | 1 | 2001 | 13 | 0.050 |
Why?
|
| Planning Techniques | 1 | 2001 | 15 | 0.050 |
Why?
|
| Nurse Administrators | 1 | 2001 | 6 | 0.050 |
Why?
|
| Immunodominant Epitopes | 2 | 1998 | 61 | 0.050 |
Why?
|
| Time Management | 1 | 2001 | 16 | 0.050 |
Why?
|
| Dendritic Cells | 2 | 1998 | 1085 | 0.050 |
Why?
|
| Professional Staff Committees | 1 | 2001 | 30 | 0.050 |
Why?
|
| Case Management | 1 | 2001 | 35 | 0.050 |
Why?
|
| Alleles | 3 | 2006 | 2437 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 4320 | 0.050 |
Why?
|
| Informed Consent | 1 | 2004 | 419 | 0.050 |
Why?
|
| Problem Solving | 1 | 2001 | 85 | 0.050 |
Why?
|
| Research Design | 1 | 2008 | 1544 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2012 | 3251 | 0.050 |
Why?
|
| Catheter Ablation | 1 | 2006 | 620 | 0.050 |
Why?
|
| Efficiency, Organizational | 1 | 2001 | 88 | 0.050 |
Why?
|
| Skin | 1 | 2005 | 1259 | 0.050 |
Why?
|
| Histocompatibility Testing | 2 | 1999 | 447 | 0.050 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2018 | 598 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2014 | 4314 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 225 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 3472 | 0.040 |
Why?
|
| Major Histocompatibility Complex | 1 | 1999 | 91 | 0.040 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2010 | 2104 | 0.040 |
Why?
|
| Patient Selection | 2 | 2018 | 2055 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2001 | 213 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2001 | 313 | 0.040 |
Why?
|
| HLA-A Antigens | 1 | 1999 | 102 | 0.040 |
Why?
|
| Algorithms | 2 | 2008 | 3890 | 0.040 |
Why?
|
| DNA Repair | 1 | 2006 | 1872 | 0.040 |
Why?
|
| Second-Look Surgery | 1 | 2018 | 14 | 0.040 |
Why?
|
| Radiotherapy Dosage | 3 | 2015 | 3842 | 0.040 |
Why?
|
| Neoplasm, Residual | 2 | 2015 | 1656 | 0.040 |
Why?
|
| Rhabdomyosarcoma | 1 | 2001 | 341 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 2594 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2014 | 4638 | 0.040 |
Why?
|
| Oliguria | 1 | 1997 | 18 | 0.040 |
Why?
|
| Sarcoma, Ewing | 1 | 2001 | 406 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2006 | 1112 | 0.040 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 1998 | 219 | 0.040 |
Why?
|
| Freund's Adjuvant | 1 | 1996 | 43 | 0.040 |
Why?
|
| Mohs Surgery | 1 | 2018 | 98 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 344 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2018 | 285 | 0.040 |
Why?
|
| Clinical Trials as Topic | 2 | 2004 | 3719 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2002 | 1234 | 0.040 |
Why?
|
| Back Pain | 1 | 2016 | 61 | 0.040 |
Why?
|
| Standard of Care | 1 | 2018 | 243 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2006 | 4821 | 0.030 |
Why?
|
| Musculoskeletal Diseases | 1 | 2016 | 81 | 0.030 |
Why?
|
| Biopsy | 2 | 2014 | 3443 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2018 | 289 | 0.030 |
Why?
|
| Comorbidity | 2 | 2014 | 2352 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2001 | 795 | 0.030 |
Why?
|
| Economics, Pharmaceutical | 1 | 2014 | 13 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 460 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 375 | 0.030 |
Why?
|
| Peptide Fragments | 2 | 1998 | 1271 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 672 | 0.030 |
Why?
|
| Communication | 1 | 2001 | 876 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 760 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1997 | 709 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2016 | 1165 | 0.030 |
Why?
|
| Models, Economic | 1 | 2014 | 101 | 0.030 |
Why?
|
| Kinesthesis | 1 | 2013 | 6 | 0.030 |
Why?
|
| Death Certificates | 1 | 2013 | 17 | 0.030 |
Why?
|
| Translations | 1 | 2013 | 39 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2015 | 200 | 0.030 |
Why?
|
| Leisure Activities | 1 | 2012 | 17 | 0.030 |
Why?
|
| France | 1 | 2013 | 108 | 0.030 |
Why?
|
| HLA Antigens | 1 | 1995 | 546 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2018 | 1274 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1998 | 1033 | 0.030 |
Why?
|
| Monocytes | 1 | 1996 | 788 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 1290 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2017 | 1819 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2014 | 702 | 0.030 |
Why?
|
| Pressure | 1 | 2012 | 215 | 0.030 |
Why?
|
| Apoptosis | 1 | 2006 | 7591 | 0.030 |
Why?
|
| Causality | 1 | 2012 | 178 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 1048 | 0.030 |
Why?
|
| ROC Curve | 1 | 2014 | 1183 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2013 | 272 | 0.020 |
Why?
|
| Aziridines | 1 | 1990 | 17 | 0.020 |
Why?
|
| Fatty Acids, Essential | 1 | 1990 | 5 | 0.020 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 1990 | 36 | 0.020 |
Why?
|
| Fatigue | 1 | 2016 | 1239 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2014 | 1944 | 0.020 |
Why?
|
| Limb Salvage | 1 | 2011 | 162 | 0.020 |
Why?
|
| Cause of Death | 1 | 2013 | 752 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2012 | 485 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2011 | 1538 | 0.020 |
Why?
|
| Proteins | 1 | 1998 | 1963 | 0.020 |
Why?
|
| Telomere | 1 | 2012 | 505 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 1910 | 0.020 |
Why?
|
| Insurance Claim Review | 1 | 2009 | 70 | 0.020 |
Why?
|
| Vinblastine | 1 | 2010 | 453 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2011 | 298 | 0.020 |
Why?
|
| Rural Population | 1 | 2010 | 281 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 2008 | 159 | 0.020 |
Why?
|
| Animals | 3 | 2011 | 59536 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1990 | 224 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 5159 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2012 | 1914 | 0.020 |
Why?
|
| Melphalan | 1 | 2011 | 834 | 0.020 |
Why?
|
| Laparotomy | 1 | 2008 | 211 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2014 | 851 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2009 | 665 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2012 | 1026 | 0.020 |
Why?
|
| Antigen Presentation | 2 | 1998 | 272 | 0.020 |
Why?
|
| Adrenalectomy | 1 | 2008 | 188 | 0.020 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2006 | 69 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 823 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2006 | 62 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 1990 | 402 | 0.020 |
Why?
|
| Remission Induction | 1 | 2012 | 3569 | 0.020 |
Why?
|
| Sunburn | 1 | 2005 | 35 | 0.020 |
Why?
|
| Sunlight | 1 | 2006 | 79 | 0.020 |
Why?
|
| DNA Primers | 1 | 2008 | 1399 | 0.020 |
Why?
|
| Endonucleases | 1 | 2006 | 178 | 0.020 |
Why?
|
| Skin Ulcer | 1 | 2006 | 77 | 0.020 |
Why?
|
| Mutation | 1 | 2005 | 15179 | 0.020 |
Why?
|
| Retreatment | 1 | 2007 | 452 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2006 | 150 | 0.020 |
Why?
|
| Gastrectomy | 1 | 2008 | 451 | 0.020 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2006 | 170 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2006 | 246 | 0.020 |
Why?
|
| Contrast Media | 1 | 2012 | 1472 | 0.020 |
Why?
|
| Microsurgery | 1 | 2007 | 244 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2006 | 460 | 0.020 |
Why?
|
| Esophagogastric Junction | 1 | 2008 | 543 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 1323 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 726 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2007 | 604 | 0.020 |
Why?
|
| Hospitalization | 1 | 2013 | 2083 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2006 | 297 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2011 | 3005 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 2086 | 0.010 |
Why?
|
| Lymph | 1 | 2003 | 76 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2016 | 8223 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 1618 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2005 | 538 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2010 | 1996 | 0.010 |
Why?
|
| Ligation | 1 | 2003 | 193 | 0.010 |
Why?
|
| Sepsis | 1 | 2008 | 652 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2016 | 2947 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1990 | 830 | 0.010 |
Why?
|
| Base Sequence | 1 | 2008 | 4917 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 2315 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 2 | 2013 | 5061 | 0.010 |
Why?
|
| Rats, Inbred BB | 2 | 1990 | 8 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2004 | 739 | 0.010 |
Why?
|
| Fowlpox virus | 1 | 1998 | 4 | 0.010 |
Why?
|
| HLA-DQ alpha-Chains | 1 | 1998 | 23 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1998 | 84 | 0.010 |
Why?
|
| HLA-DQ Antigens | 1 | 1998 | 58 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 1998 | 79 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 1998 | 259 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1998 | 284 | 0.010 |
Why?
|
| Histological Techniques | 1 | 1996 | 65 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1997 | 226 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1998 | 408 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1998 | 613 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1995 | 173 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 3343 | 0.010 |
Why?
|
| Specimen Handling | 1 | 1997 | 299 | 0.010 |
Why?
|
| Immunization | 1 | 1996 | 397 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 1996 | 446 | 0.010 |
Why?
|
| Vaccination | 1 | 1999 | 1123 | 0.010 |
Why?
|
| Gene Frequency | 1 | 1995 | 1163 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2006 | 5270 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1998 | 1694 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1998 | 4233 | 0.010 |
Why?
|
| Rats | 2 | 1990 | 6086 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1995 | 1681 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1998 | 6089 | 0.010 |
Why?
|
| Cancer Vaccines | 1 | 1996 | 697 | 0.010 |
Why?
|
| Peptides | 1 | 1996 | 1479 | 0.010 |
Why?
|
| Linoleic Acids | 1 | 1990 | 32 | 0.010 |
Why?
|
| Linoleic Acid | 1 | 1990 | 29 | 0.010 |
Why?
|
| Thyrotropin | 1 | 1990 | 119 | 0.010 |
Why?
|
| Thyroxine | 1 | 1990 | 116 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1990 | 503 | 0.010 |
Why?
|
| Fatty Acids | 1 | 1990 | 448 | 0.000 |
Why?
|
| Adjuvants, Immunologic | 1 | 1990 | 657 | 0.000 |
Why?
|
| Body Weight | 1 | 1990 | 1293 | 0.000 |
Why?
|
| Macrophages | 1 | 1990 | 1304 | 0.000 |
Why?
|